MedTrace Logo

Immune Modulation by Misoprostol

NCT02259309 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-01-14

No results posted yet for this study

Summary

The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.

Conditions

  • Gynecological Infection

Interventions

DRUG

Misoprostol - buccal

buccal administration

DRUG

Misoprostol - vaginal

vaginal administration

Sponsors & Collaborators

  • Gynuity Health Projects

    collaborator OTHER

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • David M. Aronoff, MD · Vanderbilt University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-07-31
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02259309 on ClinicalTrials.gov